We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Leica Biosystems Launches HistoCore PEGASUS Plus Dual-Retort Tissue Processor in Europe

By LabMedica International staff writers
Posted on 04 May 2022

Leica Biosystems (Nussloch, Germany) has launched a compact, dual-retort tissue processor, the HistoCore PEGASUS Plus. More...

For the first time, the technology will now be available to medium-sized laboratories, enabling them to optimize histopathology workflows.

Mid-sized laboratories will now be able to run multiple protocols in parallel on a single instrument, providing a solution that adapts to their workflow needs, and reduces unnecessary hands-on time. The dual retorts on HistoCore PEGASUS Plus increase capacity by 33% compared to a typical 300-cassette single-retort tissue processor. The HistoCore PEGASUS Plus builds on more than 15 years of experience with the larger HistoCore PELORIS system, and also incorporates Leica’s pioneering integrated track and trace technology, the HistoCore I-Scan. This enables laboratories to capture and store individual cassette information, user interactions, and reagent levels, delivering high confidence in the quality of results.

Labs face problems with tissue processing, creating the need for a solution to under- or over-processing. This occurs when labs have to process both biopsy and large routine tissue specimens in the same processing run. In an ideal scenario, biopsy and larger sample tissues would be processed separately using a protocol specific to the specimen. The HistoCore PEGASUS Plus tissue processor addresses this issue by bringing a scalable workflow solution to all labs of all sizes, ensuring optimal conditions for each tissue type without slowing down the lab. The HistoCore PEGASUS Plus is now available in Europe and where the CE mark is accepted for country-specific registration.

“We understand that labs are under pressure of staff shortages, increased daily throughput, and additional complexities with processing different types and sizes of tissue,” said Christine Munz, Vice President of Core Histology at Leica Biosystems. “Large, high throughput labs have confidence in the power and robust performance of our HistoCore PELORIS tissue processing technology. The new PEGASUS PLUS now brings these benefits to mid-sized labs.”

Related Links:
Leica Biosystems 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Urine Analyzer
respons® UDS100
New
Nucleic Acid Purification Instrument
QIAsymphony Connect
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The AidaBREAST assay integrates multimodal data to provide patient-specific 10-year recurrence risk and individualized predictions of radiation therapy benefit (photo courtesy of PreludeDx)

Validated Test Predicts Recurrence Risk and Radiation Benefit in Early-Stage Breast Cancer

For women with early-stage invasive breast cancer who undergo breast-conserving surgery, clinicians must assess both the risk of locoregional recurrence and the potential benefit of adjuvant radiation therapy.... Read more

Microbiology

view channel
Image: Invasive aspergillosis (IA) is a potentially life-threatening infection caused by Aspergillus mold that primarily affects people with severely weakened immune systems. (Image Credit: Adobe Stock)

Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis

Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: Natera\'s MCED assay analyzes cell-free DNA in blood to screen for multiple cancers (Image Credit: Adobe Stock)

Multi-Cancer Screening Blood Test Gains FDA Breakthrough Designation

Natera Inc.’s (Austin, TX, USA) multi-cancer early detection (MCED) assay has received Breakthrough Device designation (BDD) from the U.S. Food and Drug Administration (FDA). The assay analyzes cell-free... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.